Boston Scientific (BSX) vs Edwards Lifesciences (EW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Edwards Lifesciences (EW) has outperformed Boston Scientific (BSX) over the past year, gaining 12.0% versus a loss of 56.3%. Over five years, BSX leads with a -3.4% price change compared with -23.4% for EW. Boston Scientific is the larger company by market cap ($60.26 billion vs $49.44 billion), about 1.2 times the size.
On valuation, Boston Scientific trades at a lower forward P/E (12.3x vs 25.4x for Edwards Lifesciences). Edwards Lifesciences converts more of its revenue into profit, with a net margin of 17.7% versus 14.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSX | EW |
|---|---|---|
| Share price | $41.58 | $85.78 |
| Market cap | $60.26B | $49.44B |
| 1-day change | -1.45% | -0.81% |
| YTD return | -56.01% | +0.77% |
| 1-year return | -56.26% | +11.98% |
| 5-year return | -3.35% | -23.40% |
| P/E ratio (TTM) | 16.83 | 51.06 |
| Forward P/E | 12.29 | 25.40 |
| EPS (TTM) | $2.47 | $1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $20.07B | $6.07B |
| Revenue growth (YoY) | +19.87% | +11.55% |
| Net income (latest FY) | $2.89B | $1.07B |
| Gross margin | 69.01% | 78.01% |
| Operating margin | 18.00% | 20.84% |
| Net margin | 14.41% | 17.69% |
| 52-week high | $105.65 | $96.29 |
| 52-week low | $41.50 | $72.30 |
| Distance from 52-week high | -60.64% | -10.91% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +44.06% | +18.86% |
| Average volume | 19.67M | 3.82M |
| Shares outstanding | 1.45B | 576.40M |
| Employees | 59,000 | 16,000 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EW has outperformed BSX by 68.2 percentage points over the past year.
- Edwards Lifesciences trades at a higher earnings multiple (51.1x vs 16.8x trailing P/E).
- Boston Scientific grew revenue faster in its latest fiscal year (+19.87% vs +11.55%).
About Boston Scientific
BSX stock →Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Healthcare · Medical Devices · 59,000 employees
About Edwards Lifesciences
EW stock →Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
Healthcare · Medical Devices · 16,000 employees
BSX vs EW FAQ
Which is bigger, Boston Scientific or Edwards Lifesciences?
Boston Scientific (BSX) is larger, with a market capitalization of $60.26B compared with $49.44B for Edwards Lifesciences (EW).
Which stock has performed better over the past year, BSX or EW?
EW returned +11.98% over the past 12 months, compared with -56.26% for BSX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BSX or EW?
BSX has the lower trailing P/E at 16.8, versus 51.1 for EW. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Boston Scientific and Edwards Lifesciences in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.